Ocular Therapeutix, Inc (OCUL) — SEC Filings
Ocular Therapeutix, Inc (OCUL) — 41 SEC filings. Latest: 10-Q (May 5, 2026). Includes 21 8-K, 7 10-Q, 7 SC 13G/A.
View Ocular Therapeutix, Inc on SEC EDGAR
Overview
Ocular Therapeutix, Inc (OCUL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Ocular Therapeutix, Inc. filed an 8-K on December 18, 2025, reporting an event under "Other Events." The filing does not contain specific details about the event, dollar amounts, or definitive dates beyond the filing date itself.
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 2 bearish, 39 neutral. The dominant filing sentiment for Ocular Therapeutix, Inc is neutral.
Filing Type Overview
Ocular Therapeutix, Inc (OCUL) has filed 7 10-Q, 21 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G, 7 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of OCUL's 29 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $38,701,000 |
| Net Income | -$200,257,000 |
| EPS | -$1.15 |
| Debt-to-Equity | 0.59 |
| Cash Position | $344,772,000 |
| Operating Margin | -517.5% |
| Total Assets | $410,882,000 |
| Total Debt | $98,633,000 |
Key Executives
- Dr. Robert J. Langer
- Dr. David R. Walt
- Mattessich
- Dugel
- Dr. Jonathan T. Miller
- Ms. Amy T. Peterson
- Jonathan M. Miller
- Scott M. Henry
- Pravin U. Dugel, M.D.
- Frank S. Vellucci, Esq.
Industry Context
The ophthalmic pharmaceutical market is characterized by high R&D costs, lengthy clinical trial processes, and significant regulatory hurdles. Companies like Ocular Therapeutix focus on developing innovative treatments for eye diseases, often targeting unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, with success heavily dependent on pipeline advancements and successful commercialization of novel therapies.
Top Tags
8-K (5) · financial-reporting (5) · 10-Q (4) · financials (4) · personnel (4) · Biotechnology (2) · Clinical Trials (2) · Net Loss (2) · Cash Burn (2) · Ophthalmology (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 29, 2024):
- Pravin U. Dugel, M.D. — Executive Chairman, President and Chief Executive Officer
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $201.285M | for the nine months ended September 30, 2025, up from $145.118M in 2024 |
| Research and Development Expenses | $146.296M | for the nine months ended September 30, 2025, up from $86.646M in 2024 |
| Product Revenue, Net | $38.573M | for the nine months ended September 30, 2025, down from $46.441M in 2024 |
| Cash and Cash Equivalents | $344.772M | as of September 30, 2025, down from $392.102M at December 31, 2024 |
| Net Cash Used in Operating Activities | $150.634M | for the nine months ended September 30, 2025, up from $95.248M in 2024 |
| Accumulated Deficit | $1,092,369 | as of September 30, 2025, indicating significant historical losses |
| Weighted Average Common Shares Outstanding (basic) | 183,919,808 | for the three months ended September 30, 2025, up from 166,992,735 in 2024 |
| Net Loss (Q2 2025) | $29.8M | Increased from $21.5M in Q2 2024, indicating widening losses. |
| Net Loss (YTD June 2025) | $59.3M | Increased from $42.9M in YTD June 2024, showing accelerated losses. |
| Cash & Equivalents (June 30, 2025) | $100.5M | Decreased from $125.0M at Dec 31, 2024, reflecting significant cash burn. |
| R&D Expenses (Q2 2025) | $20.1M | Up from $15.5M in Q2 2024, driven by increased clinical trial activity. |
| Accumulated Deficit (June 30, 2025) | $800.5M | Highlights the company's long history of unprofitability and need for future funding. |
| Derivative Gain/Loss on Derivative and Other Net | 159262024 | Financial performance indicator for the period. |
| Derivative Liabilities Noncurrent | 157749490 | Indicates long-term financial obligations related to derivatives. |
| Filing Date | 20250429 | Indicates when the proxy statement was submitted to the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ocular Therapeutix, Inc (OCUL)?
Ocular Therapeutix, Inc has 41 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 7 10-Q, 7 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OCUL filings?
Across 41 filings, the sentiment breakdown is: 2 bearish, 39 neutral. The dominant sentiment is neutral.
Where can I find Ocular Therapeutix, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ocular Therapeutix, Inc (OCUL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ocular Therapeutix, Inc?
Key financial highlights from Ocular Therapeutix, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OCUL?
The investment thesis for OCUL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ocular Therapeutix, Inc?
Key executives identified across Ocular Therapeutix, Inc's filings include Dr. Robert J. Langer, Dr. David R. Walt, Mattessich, Dugel, Dr. Jonathan T. Miller and 5 others.
What are the main risk factors for Ocular Therapeutix, Inc stock?
Of OCUL's 29 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Ocular Therapeutix, Inc?
Forward guidance and predictions for Ocular Therapeutix, Inc are extracted from SEC filings as they are enriched.